74 results
8-K
ALBT
Avalon GloboCare Corp
14 Jun 21
Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
9:12am
activities (hematologic + solid tumor malignancies)
High tolerability and established safety profile in clinical trials to date
Provide therapies … ” while at the same time, the Guidelines for the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals issued by the International
DEFA14A
ALBT
Avalon GloboCare Corp
14 Jun 21
Additional proxy soliciting materials
9:10am
activities (hematologic + solid tumor malignancies)
High tolerability and established safety profile in clinical trials to date
Provide therapies … ” while at the same time, the Guidelines for the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals issued by the International
424B5
ALBT
Avalon GloboCare Corp
13 Dec 19
Prospectus supplement for primary offering
5:07pm
NCT03952523) for safety and efficacy studies.
AVA-101: Our transposon-based, multi-targeted CAR-T candidate, AVA-101 (co-developed with Arbele Corp … -cancer targets, as well as possessing molecular safety-switch mechanism to minimize the side effects, such as cytokine release syndrome
S-3
3aad0ex7az19g5 q5e
3 Jan 19
Shelf registration
12:00am
424B2
a7puw2
26 Apr 19
Prospectus for primary offering
5:07pm
8-K
EX-4.1
9wx7agtvsmu18pd
8 Aug 22
Entry into a Material Definitive Agreement
4:51pm
8-K
EX-4.2
gcrny67jekf257
8 Aug 22
Entry into a Material Definitive Agreement
4:51pm
8-K
EX-99.2
ey9hpg7qt3w7g
22 Oct 20
Other Events
8:36am
8-K
EX-99.1
5twaw83 1hvyn
2 May 22
Regulation FD Disclosure
4:00pm
8-K/A
EX-99.5
ai1jniz
28 Jun 21
Entry into a Material Definitive Agreement
9:18am
DEFA14A
EX-99.5
bnw7l2j
28 Jun 21
Additional proxy soliciting materials
9:16am
8-K
EX-99.1
f3yif dqq7x5
19 Aug 20
Commercialiation Partnership Agreement
9:00am
8-K
EX-4.1
xqpw uxs9bmyr3vuh
3 Apr 20
Entry into a Material Definitive Agreement
4:00pm